ZELIRA THERAPEUTICS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.47 AUD | 0.00% |
|
-2.08% | -47.78% |
| Sales 2022 | 1.54M 1.03M | Sales 2023 | 301K 201K | Capitalization | 17.13M 11.41M |
|---|---|---|---|---|---|
| Net income 2022 | -11M -7.33M | Net income 2023 | -5M -3.33M | EV / Sales 2022 | 4.57 x |
| Net cash position 2022 | 2.25M 1.5M | Net Debt 2023 | 292K 194K | EV / Sales 2023 | 57.9 x |
| P/E ratio 2022 |
-0.65
x | P/E ratio 2023 |
-2.73
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 51.29% |
More Fundamentals
* Assessed data
More news
Latest transcript on Zelira Therapeutics Limited
More press releases
| 1 week | -2.08% | ||
| 1 month | -30.88% | ||
| 3 months | -44.71% | ||
| 6 months | -47.78% | ||
| Current year | -47.78% |
1 week
0.47
0.48
1 month
0.450.70
Current year
0.450.95
1 year
0.452.40
3 years
0.459.45
5 years
0.4524.50
10 years
0.4528.00
| Managers | Title | Age | Since |
|---|---|---|---|
Oludare Odumosu
CEO | Chief Executive Officer | - | 19-11-27 |
Rahul Ganesan
DFI | Director of Finance/CFO | - | - |
Greg Blake
BRD | Director/Board Member | - | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Osagie Imasogie
CHM | Chairman | 62 | 19-11-27 |
Timothy Slate
BRD | Director/Board Member | - | 16-10-19 |
Oludare Odumosu
CEO | Chief Executive Officer | - | 19-11-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-03 | 0.47 | 0.00% | 6 729 |
| 24-05-31 | 0.47 | 0.00% | 649 |
| 24-05-30 | 0.47 | 0.00% | 1,009 |
| 24-05-29 | 0.47 | -2.08% | 4,047 |
| 24-05-28 | 0.48 | 0.00% | 9,646 |
Delayed Quote Australian S.E., June 03, 2024 at 01:56 am EDT
More quotes
Zelira Therapeutics Limited is an Australia-based biopharmaceutical company. The Company is engaged in the research, development and commercialization of clinically validated cannabinoid-based medicines. It owns a portfolio of products and a pipeline of candidates undergoing clinical development positioned to enter global markets. It is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription (Rx) business for the treatment of a variety of medical conditions, including insomnia, autism and chronic non-cancer pain, as well as offering over the counter (OTC) products. It has two medications: HOPE and ZENIVOL. ZENIVOL is a cannabinoid-based medicine for the treatment of chronic insomnia. The Company in partnership with SprinJeneCBD, introduced a full line of oral care products, including SprinJeneCBD toothpaste product, which is a hemp-derived, oral care products containing cannabinoids, blackseed oil and zinc utilizing patented technology.
Calendar
2024-08-28
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -47.78% | 3.54M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.06% | 21.96B | |
| -9.21% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- ZLD Stock
